0001193125-20-129777.txt : 20200501 0001193125-20-129777.hdr.sgml : 20200501 20200501080139 ACCESSION NUMBER: 0001193125-20-129777 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200430 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200501 DATE AS OF CHANGE: 20200501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 20838395 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 8-K 1 d901340d8k.htm 8-K 8-K
Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 0001492426 2020-04-30 2020-04-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2020

 

Horizon Therapeutics Public Limited Company

(Exact name of registrant as specified in its charter)

 

Ireland

  

001-35238

  

Not Applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: 011-353-1-772-2100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, nominal value $0.0001 per share

  

HZNP

  

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 8.01 Other Events.

On April 30, 2020, a subsidiary of Horizon Therapeutics plc (“Horizon”) entered into an agreement with Lundbeckfond Invest A/S (“Lundbeckfond”) pursuant to which Horizon acquired all of Lundbeckfond’s beneficial rights to proceeds from certain contingent future TEPEZZA (teprotumumab-trbw) milestone and royalty payments in exchange for a one-time payment of $55.0 million.

In May 2017, Horizon acquired River Vision Development Corp. (“River Vision”) and in connection with the acquisition, the previously outstanding capital stock of River Vision was converted into an up-front cash payment and rights to receive contingent future milestone and royalty payments related to TEPEZZA. The remaining aggregate potential milestone payments are $225 million and are payable based on certain TEPEZZA worldwide net sales thresholds being achieved. In addition, Horizon is obligated to pay a 3% royalty on the portion of annual worldwide net sales of TEPEZZA exceeding $300.0 million (such royalty, together with the milestone payments the “TEPEZZA Payments”). Lundbeckfond, as one of the former River Vision stockholders, held rights to receive approximately 35.66% of any future TEPEZZA Payments.

As a result of the transaction with Lundbeckfond and the previously-announced similar transaction with S.R. One, Limited, Horizon’s remaining net obligations to make TEPEZZA Payments to the former stockholders of River Vision will be reduced by an aggregate of approximately 71.32%.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 1, 2020

 

 

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

             

 

 

By:

 

/s/ Paul W. Hoelscher

 

 

 

Paul W. Hoelscher

 

 

 

Executive Vice President, Chief Financial Officer

EX-101.SCH 2 hznp-20200430.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 hznp-20200430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 hznp-20200430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE JSON 5 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d901340d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d901340d8k.htm" ] }, "labelLink": { "local": [ "hznp-20200430_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hznp-20200430_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hznp-20200430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hznp", "nsuri": "http://www.horizonoharma.com/20200430", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d901340d8k.htm", "contextRef": "duration_2020-04-30_to_2020-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d901340d8k.htm", "contextRef": "duration_2020-04-30_to_2020-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Apr. 30, 2020
Cover [Abstract]  
Entity Registrant Name Horizon Therapeutics Public Ltd Co
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001492426
Document Type 8-K
Document Period End Date Apr. 30, 2020
Entity Incorporation State Country Code L2
Entity File Number 001-35238
Entity Address, Address Line One Connaught House
Entity Address, Address Line Two 1st Floor
Entity Address, Address Line Three 1 Burlington Road
Entity Address, City or Town Dublin 4
Entity Address, Postal Zip Code D04 C5Y6
Entity Address, Country IE
City Area Code 011-353-1
Local Phone Number 772-2100
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary shares, nominal value $0.0001 per share
Trading Symbol HZNP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
ZIP 7 0001193125-20-129777-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-129777-xbrl.zip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end XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 d901340d8k_htm.xml IDEA: XBRL DOCUMENT 0001492426 2020-04-30 2020-04-30 Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 8-K 2020-04-30 L2 001-35238 Connaught House 1st Floor 1 Burlington Road Dublin 4 D04 C5Y6 IE 011-353-1 772-2100 false false false false Ordinary shares, nominal value $0.0001 per share HZNP NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #- H5 ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ ,T"A4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " S0*%0 F@',NX K @ $0 &1O8U!R;W!S+V-O M&ULS9)12\,P$,>_BN2]O:15D=#E9<,G!<&!XEM(;EM8DX;DI-VWMZU; MA^@'\#%W__SN=W"-B=)T"5]2%S&1PWPS^#9D:>**'8BB!,CF@%[GHC9'O4>H.+\'CZ2M)@T3L(@+D:G&&FD2:NK2&6_-@H^?J9UAU@"V MZ#%0!E$*8&J:&$]#V\ 5,,$(D\_?!;0+<:[^B9T[P,[)(;LEU?=]V==S;MQ! MP/OST^N\;N%")AT,CK^RDW2*N&*7R6_U>K-]9*KB%2_X7<'%EC](+F1]^S&Y M_O"["OO.NIW[Q\870=7 K[M07U!+ P04 " S0*%0F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( #- H5"I#^1$M@( %\, 8 >&PO=V]R:W-H965T&UL=5?MCMHP$'R5* ]PB3?AZP1(Y:JJE5H)7=7K;P,&HDOBU#9P M??O:3DB1=_V'Q,[,SCKC49WI]%P_63[$1K MGQRE:KBQ0W7*=*<$/WA24V>0Y].LX56;KI=^;JO62WDQ==6*K4KTI6FX^KL1 MM;RM4I;>)UZKT]FXB6R][/A)_!3F5[=5=I2-50Y5(UI=R391XKA*/['G#4P= MP2/>*G'3#_>)6\I.RG9/V[.ICS*IVGR4$<^:4VK_+V50P+FJ3)L/KOXBIJ"W>= M6(V]K+7_3?87;60S5+&M-/RCOU:MO][Z)^6=1A-@(,!_PL*OI1?RG7_FAJ^7 M2MX2U;_\CCN/V3/8=[-WD_Y5^&>V>6UGK^M\F5U=F0&QZ1'P@& C(K.U1P$@ M!<#3BP>7C[0BZ _C"AI@9(4*!%]$@A@Q)06F) "$T2?!0(8,:<% MIJ3 %-$7@0!&L)Q6F)$*,\QG@00!B?@\)R7FF!\:34 B3B](B07FAU83D(C7 M+*?CE.,*H=T4)F(XBX26X0JAYP0&(J8S.KD,<(70=@H3\9W1 6&XPS(?8PI8N[3F6?X5P7R'V,B=@"=/0!Q[J8!B($)B9")Q]PJHMPAQ&8 MF$CDDXU#7ID)XT]9?JSX%%*(VRY_,DV M?;:G_7%0BZ-QMS-[K_HC;S\PLAN.\]GXGV+]#U!+ P04 " S0*%05DV/ M7'<" "D!@ % 'AL+W-H87)E9%-T&ULA57;;MI $'U.OV*$ M^ACB"^32BB!10QJ4E-!@J6JJ/BSV8*]D[[A[2:!?WS5.HLJ+$S_9S)DS,V2G(LF3JA"H6U;$B63-M/F7FJ MDLA2E2/JLO!"WS_S2L9%;SQ2?#S2XRDEID2A@8D49D)SO8.Y:!@XB9&GQR.O MAC;P225/8. ?0^B'?ML8T2-*^#59*RU9HG^W[<_T]YCQ&F&#+EB);=0U2?Z7 M!,0Y2E:AT3Q1L#3K@B=PJU.(J(,W9EN8I[86ON')/GM8F'*-LHWW_;[?/$YY M5HIT+\=5P;*V=<,*Y:3['#RR3I(55KL4MW"#.S>H'PP_A8%;+A#NA!,\(B&8R7(-UV0Z>W&8+GYR M!B=0=:.)G(3?)LHE.J$#^&)DP46FK8KWQ-+W**/ZBR3$].1LV;2>=@'#]SB6 MI+2=N0=>'6S5U!]"=/K3&3@GE:;=;=A\YLB_=[,'Y6 X/ZB[/.@'SLA08K-< MYB2Z!N3\/.R'@;N//R37&H4-5Y;V!C9;K=JH%=G;P+45'[[9\96<%6W(4N*> M!$6"S:[91;?'ZFZS<;-QP'.EC 6_Y;/"Q,A:GB!<0\QUX/#>+B:KZ>1[QXS,2I19'?6KI">=U[)43/PW*I[]>QK_ U!+ P04 " S M0*%0NJ$YBM6QETG;:!W$RGQW9_O4G3V]$'\>"#OC0SWTR^^7*9-.MQ MDO#2 2 9E=1]3CM$^XZQONI \?Z-L:!]I#%.5&;0F-,39476&+TC=S0"/I4K(!09_"9'%/D_6*VP=GY+TGNX3YL$7*8VKP6UE$KI"12:A"7*<:+LP MHK$L!!&-\D8M><GS6L,Q;#TU8@Y4LXPJ_-%??8D)CSL0['0(**U?2K7LQX M7-$)_$>VR'V@O;^)EEAQ,?AA\*O1L_]M, C/#AHQSO[8;/4].[=63N^E:+6" MN);?%DQN+%AD?*U#.N/$J^<+-Z7R #A*+N!05$?DN^/V#".NMVEL;M6<_H>: M__8^MZ#!<7D4[:_^O[S+?Z*8+=US:-&K!MU04@Y"HM"+QD[4-41YX87,Z9?P M\,JK/MG[U-,C+_T#?L7OY];0\$'BG)P_E,X=Q)?1-A2R)>KF61:J%HP*-ZX#RYW&>:.(2[_/ M0N=!U:$%(*.S:9[/,J/0RN5BU-KX[+IP!!6ALPQ&8(=P"I=^+(5BPA$^55G( M7 K5DWM"3>!7BN#9N[Y#NR_D1(H&?:!MG)V8!BT:/$.=JM"ZTXOS>':6E-Y6 MWFF=7L5&>L03PB^R T]8_2&2*C\4>RWD+&?!(P8L42-]%S+=-4C>(KM:(^4P MGD.(<_^?&%W38 4K5_4&+ TY>M!QN@TM=D$*JPP43>PZ[ MU_J!L7?[ZE32CQKCQRU_ %!+ P04 " S0*%0_\ F"+T "% @ &@ M 'AL+U]R96QS+W=OE%!H0=%#(\='E\Q4??TEUG/7H(PK8>_R43]-<#JUV5?4$L#!!0 ( M #- H5 +C]@#(0$ %<$ 3 6T-O;G1E;G1?5'EP97-=+GAM;+5434_# M, S]*U.O:,W@P %MNP!7F 1_("1N&S5?LKW1_7O<;D-B*F)HVR6)\^SW7A(K M\_=M!IITP4=:% US?E"*3 -!4YDR1$&JA$&SA%BKK$VK:U!WL]F],BDR1)YR MSU$LYT]0Z;7GR>-NOZ=>%#IG[XQFEZ+:1'M$.MT3E@A^R*'&9;J1A&+RW D+ MR=ZB$)0*=8+"<6$?2]WK!A"=A7]92U7E#-ADUD%*2LH(VE(#P,&7U&@$^\;H M8KWWN]+(+SH(L>J\^I%07L\';SV,&QB02RJSM 6,20W ;KP]2_#0#28A3#,* MBNQ&CB>65H*2ZA,O>43H6\>"/4E&UL4$L! A0#% M @ ,T"A4*D/Y$2V @ 7PP !@ ( !]P@ 'AL+W=O7!E&UL4$L%!@ * H @ ( $44 ! $! end XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.horizonoharma.com//20200430/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d901340d8k.htm hznp-20200430.xsd hznp-20200430_lab.xml hznp-20200430_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}